Seminars in Arthritis and Rheumatism
Volume 40, Issue 3 , Pages 233-240 , December 2010

Psoriatic Skin Lesions Induced by Tumor Necrosis Factor Antagonist Therapy: Clinical Features and Possible Immunopathogenesis

  • Angelique N. Collamer, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Angelique N. Collamer, MD, Rheumatology Service, Brooke Army Medical Center, 3851 Roger Brooke Drive, Fort Sam Houston, TX 78234
    • ,
  • Daniel F. Battafarano, DO

References 

  1. Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Sieper J, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis. 2007;66(Suppl III):iii2–iii22
  2. Callen JP. Complications and adverse reactions in the use of newer biologic agents. Semin Cutan Med Surg. 2007;26:6–14
  3. Zeichner JA, Lebwohl M. Potential complications associated with the use of biologic agents for psoriasis. Dermatol Clin. 2007;25:207–213
  4. Moreland LW, Weinblatt ME, Keystone EC, Kremer JM, Martin RW, Schiff MH, et al. Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience. J Rheumatol. 2006;33:854–861
  5. Collamer AN, Guerrero KT, Henning JS, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum. 2008;59:996–1001
  6. Harrison MJ, Dixon WG, Watson KD, King Y, Groves R, Hyrich KL, et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor-α therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2009;68:209–215
  7. Gottlieb AB, Matheson RT, Lowe N, Krueger GG, Kang S, Goffe BS, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol. 2003;139:1627–1632
  8. Baeten D, Kruithof E, Van den Bosch F, Van den Bossche N, Herssens A, Mielants H, et al. Systematic safety follow-up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defense in the pathogenesis of the disease?. Ann Rheum Dis. 2003;62:829–834
  9. Jarrett SJ, Cunnane G, Conaghan PG, Bingham SJ, Buch MH, Quinn MA, et al. Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. J Rheumatol. 2003;30:2287–2291
  10. Haibel H, Spiller I, Strassere C. Unexpected new onset or exacerbation of psoriasis in treatment of active ankylosing spondylitis with TNF-alpha blocking agents: four case reports. Ann Rheum Dis. 2004;63:405
  11. Beuthien W, Mellighoff HU, von Kempis J. Skin reaction to adalimumab. Arthritis Rheum. 2004;50:1690–1692
  12. Kary S, Worm M, Fritz J, Audring H, Scherer HU, Lee H, et al. New onset or aggravation of psoriatic skin lesions in patients with definite rheumatoid arthritis under treatment with TNF-alpha antagonists: report of 8 cases. Ann Rheum Dis. 2004;63:276
  13. Verea M, Del Pozo J, Yebra-Pimentel M, Porta A, Fonseca E. Psoriasiform eruption induced by infliximab. Ann Pharmacother. 2004;38:54–57
  14. Thurber M, Feasel A, Stroehlein J, Hymes SR. Pustular psoriasis induced by infliximab. J Drugs Dermatol. 2004;3:439–440
  15. Dereure O, Guillot B, Jorgensen C, Cohen JD, Combes B, Guilhou JJ. Psoriatic lesions induced by anti-tumor necrosis factor alpha treatment: two cases. Br J Dermatol. 2004;150:506–507
  16. Flendrie M, Vissers WH, Creemers MC, de Jong EM, van de Kerkhof PC, van Riel PL. Dermatological conditions during TNF-alpha blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther. 2005;7:666–676
  17. Grinblat B, Scheinberg M. Unexpected onset of psoriasis during infliximab treatment: comment on the article by Beuthien et al. [letter]. Arthritis Rheum. 2005;52:1333–1334
  18. Sifkakis PP, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum. 2005;52:2513–2518
  19. Peramiquel L, Puig L, Dalmau J, Ricart E, Roe E, Alomar A. Onset of flexural psoriasis during infliximab treatment for Crohn's disease. Clin Exp Derm. 2005;30:713–714
  20. Michaelsson G, Kajermo U, Michaelsson A, Hagforsen E. Infliximab can precipitate as well as worsen palmoplantar pustulosis: possible linkage to the expression of tumor necrosis factor alpha in the normal palmar eccrine sweat duct?. Br J Dermatol. 2005;153:1243–1244
  21. Starmans-Kool MJF, Peeters HRM, Houben HHM. Pustular skin lesions in patients treated with infliximab: report of two cases. Rheumatol Int. 2005;25:550–552
  22. Zarnitsky C, Bravard P, Godon J, et al. Pustulose palmaire et plantaire chez une patiente traite′e par adalimumab [abstract]. Rev Rhum. 2005;72:1195
  23. Solau-Gervais E, Lebas D, Duquesnoy B, et al. Cutaneous modifications during anti-TNF therapy in rheumatoid arthritis [abstract]. Ann Rheum Dis. 2005;64(Suppl III):458
  24. Djeanne S, Oro S, Lévy-Weil FE, et al. Psoriasis cutané induit par traitement anti-TNF alpha au cours d'une fasciite éosinophile [abstract]. Rev Rhum. 2005;72:1183
  25. González-López MA, Blanco-Alonso R, Yáñez-Díaz S, Fernández-Llaca H. Psoriasis inducida por infliximab: un hecho paradójico [letter]. Med Clin (Barc). 2006;127:316
  26. Ritchlin C, Tausk F. A medical conundrum: onset of psoriasis in patients receiving anti-tumour necrosis factor agents. Ann Rheum Dis. 2006;65:1541–1544
  27. Matthews C, Rogers S, FitzGerald O. Development of new-onset psoriasis while on anti-TNF alpha treatment. Ann Rheum Dis. 2006;65:1529–1530
  28. Goncalves DP, Laurindo I, Scheinberg M. The appearance of pustular psoriasis during antitumor necrosis factor therapy. J Clin Rheumatol. 2006;12:262
  29. Peek R, Scott-Jupp R, Strike H, Clinch J, Ramanan AV. Psoriasis after treatment of juvenile idiopathic arthritis with etanercept. Ann Rheum Dis. 2006;65:1259
  30. Kary S, Worm M, Audring H, Huscher D, Renelt M, Sorensen H, et al. New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists. Ann Rheum Dis. 2006;65:405–407
  31. Sari I, Akar S, Birlik M, Sis B, Onen F, Akkoc N. Anti-tumor necrosis factor alpha-induced psoriasis. J Rheumatol. 2006;33:1411–1414
  32. Adams DR, Buckel T, Sceppa JA. Infliximab associated new-onset psoriasis. J Drugs Dermatol. 2006;5:178–179
  33. Pirard D, Arco D, Debrouckere V, Heenen M. Anti-tumor necrosis factor alpha-induced psoriasiform eruptions: three further cases and current overview. Dermatology. 2006;213:182–186
  34. Volpe A, Caramaschi P, Carlett A, Pieropan S, Bambara LM, Biasi D. Psoriasis onset during infliximab treatment: description of two cases. Rheumatol Int. 2006;26:1158–1160
  35. Massara A, Cavazzini PL, Trotta F. In SAPHO syndrome anti-TNF-α therapy may induce persistent amelioration of osteoarticular complaints, but may exacerbate cutaneous manifestations. Rheumatology. 2006;45:730–733
  36. Cassano N, Coviello C, Loconsole F, Miracapillo A, Vena GA. Psoriasis exacerbation after a flu-like syndrome during anti-TNF-alpha therapy. Eur J Dermatol. 2006;16:316–317
  37. Takahashi H, Hashimoto Y, Ishida-Yamamoto A, Ashida T, Kohgo Y, Iizuka H. Psoriasiform and pustular eruption induced by infliximab. J Dermatol. 2007;34:468–472
  38. Cavailhes A. Occurrence of psoriasis in a patient presenting Shulman fasciitis treated with infliximab. Ann Dermatol Venereol. 2007;134:363–367
  39. Goiriz R, Dauden E, Perez-Gala S, Guhl G, Garcia-Diez A. Flare and change of psoriasis morphology during the course of treatment with tumour necrosis factor blockers. Clin Exp Dermatol. 2007;32:176–179
  40. Lee HH, Song IH, Friedrich M, Gauliard A, Detert J, Rowert J, et al. Cutaneous side effects in patients with rheumatoid diseases during application of tumor necrosis factor alpha antagonists. Br J Dermatol. 2007;156:486–491
  41. de Gannes G, Ghoreishi M, Pope J, Russell A, Bell D, Adams S, et al. Psoriasis and pustular dermatitis triggered by TNF-α inhibitors in patients with rheumatologic conditions. Arch Dermatol. 2007;143:223–231
  42. Cohen JD, Bournerias I, Buffard V, Paufler A, Chevalier X, Bagot M, et al. Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series. J Rheumatol. 2007;34:380–385
  43. Angelucci E. Another paradox in Crohn's disease: new onset of psoriasis in a patient receiving tumor necrosis factor-alpha antagonist. Inflam Bowel Dis. 2007;13:1059–1061
  44. Wegscheider BJ, El-Shabrawi L, Weger M, Ardjomand N, Hermann J, Aberer E, et al. Adverse skin reactions to infliximab in the treatment of intraocular inflammation. Eye. 2007;21:547–549
  45. Roux CH, Brocq O, Leccia N, Giacchero D, Breuil V, Albert C, et al. New-onset psoriatic palmoplantaris pustulosis following infliximab therapy: a class effect?. J Rheumatol. 2007;34:434–437
  46. Richette P, Viguier M, Bachelez H, Bardin T. Psoriasis induced by anti-tumor necrosis factor therapy: a class effect?. J Rheumatol. 2007;34:438–439
  47. Ubriani R. Onset of psoriasis during treatment with TNF-α antagonists: a report of 3 cases. Arch Dermatol. 2007;143:270–272
  48. Severs G, Lawlor T, Purcell S, Adler D, Thompson R. Cutaneous reaction to infliximab: report of psoriasis developing in 3 patients. Cutis. 2007;80:231–237
  49. Passarini B, Infusino SD, Barbieri E, Varotti E, Gionchetti P, Rizzello F, et al. Cutaneous manifestations in inflammatory bowel diseases: eight cases of psoriasis induced by anti-tumor-necrosis-factor antibody therapy. Dermatology. 2007;215:295–300
  50. Sladden MJ, Clarke PJ, Wettenhall J. Infliximab-induced palmoplantar pustulosis in a patient with Crohn disease. Arch Dermatol. 2007;143:1449
  51. Martínez-Morán C, Sanz-Muñoz C, Morales-Callaghan AM, Torrero V, Miranda-Romero A. Pustular psoriasis induced by infliximab. JEADV. 2007;21:1424–1426
  52. Lebas D, Staumont-Sallé D, Solau-Gervais E, Flipo RM, Delaporte E. Cutaneous manifestations during treatment with TNF-alpha blockers: 11 cases. Ann Dermatol Venereol. 2007;134:337–342
  53. Bruzzese V. Psoriasi suberitrodermica diffusa indotta da infliximab [Diffused suberitrodermic psoriasis induced by infliximab]. Reumatismo. 2007;59:328–331
  54. Uriarte Itzazelaia E, Hernando I, Prada A, Alonso A. Severe bout of cutaneous psoriasis in a patient with psoriasic arthritis undergoing treatment with infliximab. Clin Exp Rheumatol. 2007;25:659
  55. Umeno J, Matsumoto T, Jo Y, Ichikawa M, Urabe K, Iida M. Psoriasis during anti-tumor necrosis factor-alpha therapy for Crohn's disease. Inflamm Bowel Dis. 2007;13:1188–1189
  56. Pérez-Pérez L, Caeiro JL, Fabeiro JM, Allegue F, Zulaica A. Induction of pustular lesions during infliximab therapy for Crohn's disease. Acta Derm Venereol. 2008;88:292–293
  57. Borrás-Blasco J, Gracia-Perez A, Nuñez-Cornejo C, Rosique-Robles JD, Mateu-Puchades A, Casterá MDE, et al. Exacerbation of psoriatic skin lesions in a patient with psoriatic arthritis receiving adalimumab. J Clin Pharm Ther. 2008;33:321–325
  58. Boms S, Sehr T, Jappe U, Enk A. First manifestation of psoriasis vulgaris in tumor necrosis factor receptor-associated periodic syndrome during treatment with etanercept. Hautarzt. 2008;59:653–655
  59. Aslanidis S, Pyrpasopoulou A, Douma S, Triantafyllou A. Tumor necrosis factor-α antagonist induced psoriasis: yet another paradox in medicine. Clin Rheumatol. 2008;27:377–380
  60. Mössner R, Thaci D, Mohr J, Pätzold S, Bertsch HP, Krüger U, et al. Manifestation of palmoplantar pustulosis during or after infliximab therapy for plaque-type psoriasis: report on 5 cases. Arch Dermatol Res. 2008;300:101–105
  61. Papadavid E, Gazi S, Dalamaga M, Stavrianeas N, Ntelis V. Palmoplantar and scalp psoriasis occurring during anti-tumour necrosis factor-α therapy: a case series of four patients and guidelines for management. J Eur Acad Dermatol Venereol. 2008;22:380–381
  62. Chan CY, Browning JC, Larsen F, Hsu S. Development of new-onset psoriasis in a patient receiving infliximab for treatment of rheumatoid arthritis. Dermatol Online J. 2008;14:12
  63. Richetta AG, Mattozzi C, Carlomagno V, Maiani E, Carboni V, Giancristoforo S, et al. A case of infliximab-induced psoriasis. Dermatol Online J. 2008;14:9
  64. Costa-Romero M. Guttate psoriasis induced by infliximab in a child with Crohn's disease. Inflamm Bowel Dis. 2008;14:1462–1463
  65. Cuchacovich R, Espinoza CG, Virk Z, Espinoza LR. Biologic therapy (TNF-α antagonists)-induced psoriasis (A cytokine imbalance between TNF-α and IFN-α?). J Clin Rheumatol. 2008;14:353–356
  66. Wollina U. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol. 2008;9:1–14
  67. Wendling D, Balblanc JC, Briancon D, Brousse A, Lohse A, Deprez P, et al. Onset or exacerbation of cutaneous psoriasis during TNFα antagonist therapy. Joint Bone Spine. 2008;75:315–318
  68. Bosch RI, Amo Ndel V, Manteca CF, Cortina EL, Polo RG, Courel LG. Psoriasis induced by anti-TNF probably not so uncommon. J Clinical Rheumatol. 2008;14:128
  69. Bal A, Gurcay E, Aydog E, Umay E, Tatlican S, Cakci A. Onset of psoriasis induced by infliximab. J Clin Rheumatol. 2008;14:129
  70. Pérez-Zafrilla B, García de Yébenes M, Dauden E, Gómez-Reino JJ, Carmona L. Is psoriasis a complication of anti-TNF treatment?. Arthritis Rheum. 2008;58(Suppl):S781
  71. Egnatios G, Warthan MM, Pariser R, Hood AF. Pustular psoriasis following treatment of rheumatoid arthritis with TNF-alpha inhibitors. J Drugs Dermatol. 2008;7:975–977
  72. Exarchous S, Voulgari P, Markatseli T, Zioga A, Drosos A. Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors. Scand J Rheumatol. 2009;4:1–4
  73. Bordel-Gómez MT, Sánchez-Estella J, Martínez-González O, Cardeñoso-Alvarez ME. Palmoplantar psoriasis: a paradoxical adverse reaction induced by adalimumab. J Eur Acad Dermatol Venereol. 2009;23:444–445
  74. English PL, Vender R. Occurrence of plantar pustular psoriasis during treatment with infliximab. J Cutan Med Surg. 2009;13:40–42
  75. Monteagudo Sánchez B, Cabanillas M, Ortiz-Marin S, Gallego-Ojea JC. Psoriasis pustulosa inducida por infliximab en una paciente con enfermedad de Crohn [Infliximab-induced pustular psoriasis in a patient with Crohn's disease]. Gastroenterol Hepatol. 2009;32:175–176
  76. Harris MD, Richards R. First case report of adalimumab-induced psoriasis in Crohn's disease. Am J Gastroenterol. 2009;104:792–793
  77. Wermuth J, Kind F, Steuerwald M. Palmoplantar pustulosis and acrodermatitis in a patient treated with infliximab for Crohn's sacroiliitis. Clin Gastroenterol Hepatol. 2009;7:A28
  78. Avila Alvarez A, García-Alonso L, Solar Boga A, García-Silva J. Psoriasis secundaria al tratamiento con infliximab y adalimumab en la enfermedad de Crohn [Flexural psoriasis induced by infliximab and adalimumab in a patient with Crohn's disease]. An Pediatr (Barc). 2009;70:278–281
  79. Fouache D, Goëb V, Massy-Guillemant N, Avenel G, Bacquet-Deschryver H, Kozyreff-Meurice M, et al. Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study. Rheumatology (Oxford). 2009;48:761–764
  80. El Shabrawi-Caelen L, La Placa M, Vincenzi C, Haidn T, Muellegger R, Tosti A. Adalimumab-induced psoriasis of the scalp with diffuse alopecia: a severe potentially irreversible cutaneous side effect of TNF-alpha blockers. Inflamm Bowel Dis. 2010;16:182–183
  81. United States Food and Drug Administration. Postmarket Drug Safety Information for Patients and Providers (FDA Alert 8/4/2009: Information for Healthcare Professionals: Tumor Necrosis Factor (TNF) Blockers (marketed as Remicade, Enbrel, Humira, Cimzia and Simponi)). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm174474.htmAccessed 15 September 2009
  82. Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1 (Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics). J Am Acad Dermatol. 2008;58:826–850
  83. Turkiewicz A, Moreland L. Psoriatic arthritis: current concepts on pathogenesis-oriented therapeutic options. Arthritis Rheum. 2007;56:1051–1066
  84. Bernstein CN, Wajda A, Blanchard JF. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology. 2005;129:827–836
  85. Farkas L, Beiske K, Lund-Johansen F, Brandtzaeg P, Jahnsen FL. Plasmacytoid dendritic cells (natural interferon-α/β-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol. 2001;159:237–243
  86. Gilliet M, Conrad C, Geiges M, Cozzio A, Thurlimann W, Burg G, et al. Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch Dermatol. 2004;140:1490–1495
  87. Palucka AK, Blanck JP, Bennett L, Pascual V, Banchereau J. Cross-regulation of TNF and IFN-α in autoimmune diseases. Proc Natl Acad Sci USA. 2005;102:3372–3377
  88. Nissinen R, Leirisalo-Repo M, Peltomaa R, Palosuo T, Vaarala O. Cytokine and chemokine receptor profile of peripheral blood mononuclear cells during treatment with infliximab in patients with active rheumatoid arthritis. Ann Rheum Dis. 2004;63:681–687
  89. Nestle FO, Conrad C, Tun-Kyi A, Homey B, Gombert M, Boyman O, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-α production. J Exp Med. 2005;202:135–143
  90. Aeberli D, Oertle S, Mauron H, Reichenbach S, Jordi B, Villiger P, et al. Inhibition of the TNF-pathway: use of infliximab and etanercept as remission-inducing agents in cases of therapy-resistant chronic inflammatory disorders. Swiss Med Wkly. 2002;132:414–422
  91. Eriksen KW, Lovato P, Skov L, Krejsgaard T, Kaltoft K, Geisler C, et al. Increased sensitivity to interferon-α in psoriatic T cells. J Invest Dermatol. 2005;125:936–944
  92. Nestle FO, Kaplan DH, Barker J. Psorasis. N Engl J Med. 2009;361:496–509
  93. Aeberli D, Seitz M, Juni P, Villiger PM. Increase of peripheral CXCR3 positive T lymphocytes upon treatment of RA patients with TNF-α inhibitors. Rheumatology. 2005;44:172–175
  94. Maurice MM, van der Graaff WL, Leow A, Breedveld FC, van Lier RA, Verweij CL. Treatment with monoclonal anti-tumor necrosis factor alpha antibody results in an accumulation of Th1 CD4+ T cells in the peripheral blood of patients with rheumatoid arthritis. Arthritis Rheum. 1999;42:2166–2173
  95. Rottman JB, Smith TL, Ganley KG, Kikuchi T, Krueger JG. Potential role of the chemokine receptors CXCR3, CCR4, and the integrin alphaEbeta7 in the pathogenesis of psoriasis vulgaris. Lab Invest. 2001;81:335–347
  96. Richez C, Schaeverbeke T, Dumoulin C, Dehais J, Moreau J, Blanco P. Myeloid dendritic cells correlate with clinical response whereas plasmacytoid dendritic cells impact autoantibody development in rheumatoid arthritis patients treated with infliximab. Arthritis Res Ther. 2009;11:R100
  97. Eriksson MO, Hagforsen E, Lundin IP, Michaelsson G. Palmoplantar pustulosis: a clinical and immunohistological study. Br J Dermatol. 1998;138:390–398
  98. Routhouska SB, Sheth PB, Korman NJ. Long-term management of generalized pustular psoriasis with infliximab: case series. J Cutan Med Surg. 2008;12:184–188
  99. Dutz JP. Tumor necrosis factor-α inhibition and palmoplantar pustulosis: Janus-faced therapy?. J Rheumatol. 2007;34:247–249
  100. Dass S, Vital EM, Emery P. Development of psoriasis after B cell depletion with rituximab. Arthritis Rheum. 2007;56:2715–2718
  101. Mielke F, Schneider-Obermeyer J, Dörner T. Onset of psoriasis with psoriatic arthropathy during rituximab treatment of non-Hodgkin lymphoma. Ann Rheum Dis. 2008;67:1056–1057
  102. Balato A, La Bella S, Gaudiello F, Balato N. Efalizumab-induced guttate psoriasis (Successful management and re-treatment). J Dermatol Treat. 2008;19:182–184
  103. Lowes MA, Chamian F, Abello MV, Leonardi C, Dummer W, Papp K, et al. Eruptive papules during efalizumab (anti-CD11a) therapy of psoriasis vulgaris: a case series. BMC Dermatol. 2007;7:2
  104. Hassan AS, Simon D, Simon HU, Braathen LR, Yawalkar N. Efalizumab-associated papular psoriasis. Arch Dermatol. 2007;143:900–906
  105. Rallis E, Verros C, Karanikola E, Valaskatzi A, Papaconstantis M. Exacerbation of psoriasis under efalizumab therapy. J Cutan Med Surg. 2009;13:106–109
  106. González-López MA, Martinez-Taboada VM, González-Vela MC, Fernández-Llaca H, Val-Bernal JF. New-onset psoriasis following treatment with the interleukin-1 receptor antagonist anakinra. Br J Dermatol. 2008;158:1146–1148
  107. Ongaro A, De Mattei M, Pellati A, Caruso A, Ferretti S, Masieri FF, et al. Can tumor necrosis factor receptor II gene 676T>G polymorphism predict the response grading to anti-TNFalpha therapy in rheumatoid arthritis?. Rheumatol Int. 2008;28:901–908
  108. Bowcock AM. The genetics of psoriasis and autoimmunity. Annu Rev Genomics Hum Genet. 2005;6:93–122
  109. Li Y, Liao W, Chang M, Schrodi S, Bui N, Catanese JJ, et al. Further genetic evidence for three psoriasis-risk genes: ADAM33, CDKAL1, and PTPN22. J Invest Dermatol. 2009;129:629–634

 Disclaimers: The opinions or assertions contained herein are those of the authors and are not to be construed as official policy of the Department of the Army, Department of the Air Force, or the Department of Defense.

PII: S0049-0172(10)00073-9

doi: 10.1016/j.semarthrit.2010.04.003

Seminars in Arthritis and Rheumatism
Volume 40, Issue 3 , Pages 233-240 , December 2010

Article Tools